Compared to the T1 subtype, T9 CAR-T cells preferentially secrete IL-9, which displays anti-tumoral effects on both hematologic (ALL) and solid (liver carcinoma) tumors. This evidence concerns the gene IL9 and acute lymphoblastic leukemia.